EGR2 (early growth response 2) is a transcription factor with critical roles in neural development, immune regulation, and cellular differentiation. In neural tissues, EGR2 is essential for Schwann cell development and myelination, with mutations causing severe peripheral neuropathies including Charcot-Marie-Tooth disease type 1D and Dejerine-Sottas syndrome 1. The protein functions as both a transcriptional activator and an E3 SUMO-protein ligase, promoting SUMO1 conjugation to coregulators NAB1 and NAB2 to modulate its own transcriptional activity. EGR2 plays diverse physiological roles including regulation of central respiratory chemoreception in the medulla oblongata 2, maintenance of progenitor exhausted CD8+ T cell self-renewal through chr10 accessibility changes 3, and suppression of autoimmune responses by promoting inhibitory cytokine production 4. In pathological contexts, EGR2 demonstrates protective functions by directly activating GDF15 to modulate retinal microglial phenotype in autoimmune uveitis 5 and regulating cardiac hypertrophy through lncRNA control 6. Additionally, EGR2 contributes to tumor-associated Schwann cell activation and metastatic memory formation 7. These findings establish EGR2 as a multifunctional regulator with therapeutic potential across neurological, cardiovascular, and immune-related diseases.